Retatrutide Dr

Retatrutide: Frequently Asked Questions

These are the most common questions about Retatrutide answered directly from the clinical trial record. Every quantitative claim is cited. For the full research context, see the Phase 2 and Phase 3 trial results and the mechanism page.

Flat horizontal timeline rail with five phase nodes, one highlighted in warm orange
Fig. 1. Retatrutide clinical development timeline from Phase 1b through Phase 3 TRIUMPH. The orange node marks the TRIUMPH-1 Phase 3 pivotal readout (May 2026).

Is Retatrutide FDA Approved?

Regulatory status

Retatrutide is investigational as of mid-2026. No approved indication exists in the US, EU, or any other jurisdiction. The questions below address the regulatory timeline and availability in detail.

Retatrutide Availability and Regulatory Status

Not FDA approved

Retatrutide is an investigational compound with no approved indication in the US, EU, or any other jurisdiction as of mid-2026. The TRIUMPH-1 pivotal Phase 3 trial results were reported in May 2026. An NDA submission to the FDA is anticipated in Q4 2026; regulatory approval under a standard 10-month FDA review would be projected in late 2027 to Q1 2028.[21]

All Questions

  • Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly that simultaneously activates three gut hormone receptors: GIP, GLP-1, and glucagon receptors.[6] Studied in Phase 2 and Phase 3 trials primarily for obesity and type 2 diabetes, Retatrutide has produced the largest mean body weight reductions in the published obesity pharmacotherapy literature to date — 24.2% in Phase 2 and 28.3% in Phase 3 (TRIUMPH-1) at the highest dose.[1][9]

  • Retatrutide activates GLP-1 receptors (suppressing appetite and slowing gastric emptying), GIP receptors (potentiating insulin secretion and modulating adipocyte signaling), and glucagon receptors (promoting hepatic fat oxidation and brown adipose tissue thermogenesis).[6] The combined result is greater appetite suppression, greater energy expenditure, and larger weight reduction than GLP-1-only or dual GIP/GLP-1 agonists produced in separate trial programs.

  • Retatrutide binds and activates three G-protein-coupled receptors simultaneously via a single 39-amino acid peptide backbone.[6] Cryo-EM structural studies resolved the atomic mechanism: conserved salt-bridge contacts anchor the peptide across all three receptors, while receptor-specific ECL1 loop conformations allow each receptor to engage the same molecule distinctly.[6] The shared cAMP second-messenger pathway mediates appetite suppression, insulin potentiation, and thermogenesis via each receptor’s tissue-specific expression.

  • Phase 2 and Phase 3 trials have studied Retatrutide primarily in obesity (BMI ≥30 or ≥27 with comorbidities) and type 2 diabetes.[4][9] Secondary investigations cover MASLD, knee osteoarthritis with obesity,[10] cardiovascular outcomes,[21] renal effects,[18] and an oncology application in murine obesity-cancer models.[8] No approved indication exists as of mid-2026.

  • Not approved as of mid-2026. Phase 3 pivotal data (TRIUMPH-1) were reported May 2026, with an NDA submission to the FDA anticipated Q4 2026.[21] Standard FDA review takes approximately 10 months; regulatory approval is projected for late 2027 to Q1 2028 pending submission and review. Retatrutide is accessible currently only through registered clinical trials.

  • Market availability depends on NDA submission and the FDA review timeline. With submission anticipated Q4 2026 and a standard 10-month review, a plausible approval timeline is late 2027 to Q1 2028.[21] Priority review (6 months) would pull that forward if granted. These are planning projections, not guarantees — regulatory review outcomes depend on the complete data package submitted.

  • The most common adverse events in Phase 2 trials at the 12 mg dose were nausea (~60%), diarrhea (15–33%), vomiting (21–26%), constipation (11–16%), and injection-site reactions (up to 8%).[3] Phase 3 TRIUMPH-1 data at 12 mg showed nausea 42.4%, diarrhea 32.0%, constipation 26.1%, vomiting 25.3%.[23] GI events were predominantly mild to moderate and most prominent during dose-escalation weeks. See the dedicated Retatrutide side effects page for full data.

  • Beyond common GI events, monitored signals include a heart rate increase of up to 6.7 beats/min (glucagon-receptor-mediated, dose-dependent, peaking at 24 weeks in Phase 2),[16] a single atrial fibrillation event in the Phase 2 T2D cohort,[16] and theoretical class-effect concerns for pancreatitis and thyroid C-cell effects — neither were observed in Phase 3 data to date.[23] Long-term cardiovascular outcomes remain under study in TRIUMPH-OUTCOMES.

  • No Retatrutide-specific long-term discontinuation trial has been published. Class-effect data from analogous compounds show most lost weight returns within 12 months of stopping treatment: semaglutide STEP 4 documented 6.9% regain post-placebo switch; tirzepatide SURMOUNT-4 documented 14.0% regain.[19] The underlying mechanism is recovery of orexigenic signaling once appetite suppression via receptor agonism is removed.

  • Phase 2 data showed strong reductions in visceral and hepatic fat. At 48 weeks at 12 mg, participants achieved a mean 86.0% relative hepatic fat reduction, with 93% reaching normal liver fat below 5%.[15] The Phase 2a MASLD trial documented 82.4% liver fat reduction at 24 weeks at 12 mg.[7] The glucagon receptor component drives hepatic fat oxidation directly and activates brown adipose tissue thermogenesis, which may preferentially reduce visceral versus subcutaneous fat.[12]

  • Phase 2/3 trial participants experienced progressive appetite suppression beginning within the first 4 weeks, statistically significant weight loss detectable by week 8, and maximum weight reduction accruing over 48–80 weeks.[22][9] Mean outcomes in Phase 3 TRIUMPH-1 at 12 mg: 28.3% body weight reduction at 80 weeks, 45.3% achieving at least 30% loss.[9] GI adverse events were most prominent during dose-escalation and diminished at maintenance doses.[3]

  • Semaglutide is a GLP-1-only receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist that adds glucagon receptor activation on top of GIP and GLP-1R co-agonism.[6] The additional glucagon receptor engagement drives brown adipose tissue thermogenesis — a mechanism absent in the other two compounds. Indirect comparison of separate Phase 3 trials: Retatrutide at 12 mg produced 28.3% mean weight reduction at 80 weeks, exceeding published semaglutide 2.4 mg Phase 3 results (~14.9%) and tirzepatide peak data (~22.5%).[17] No controlled head-to-head trial has been published.

  • No. Retatrutide is a synthetic, engineered peptide. Its targets — GIP, GLP-1, and glucagon receptors — are activated by natural hormones, but Retatrutide itself is a designed 39-amino acid peptide with a C20 fatty diacid conjugation that does not occur in the natural hormone milieu.[14] That conjugation is what enables the ~6-day half-life supporting once-weekly dosing.[5]

  • Not yet applicable as of mid-2026. Retatrutide has no approved indication and therefore no commercial prescription pathway. It is currently accessible only through registered clinical trials.[21] A prescription pathway would open only after FDA approval of a specific indication, which is pending NDA submission anticipated in Q4 2026.

  • The “GLP-3” label sometimes applied to Retatrutide is not an official pharmacological classification.[14] The compound is accurately described as a triple GIP/GLP-1/glucagon receptor agonist or GGG triple agonist. The GLP-3 shorthand is colloquial and not recognized in pharmacological taxonomy. Retatrutide’s three receptor targets are GIPR, GLP-1R, and GCGR.

  • No published head-to-head trial exists as of mid-2026. Indirect comparison of separate Phase 3 trials: Retatrutide TRIUMPH-1 at 12 mg produced 28.3% mean weight reduction at 80 weeks; tirzepatide Phase 3 obesity program peak was approximately 22.5%.[13] In preclinical models, the triple-agonist advantage over dual agonism has been attributed to GCGR-mediated brown adipose tissue thermogenesis.[12] The NCT06662383 head-to-head trial is registered but not yet reported.

  • Approximately 6 days in Phase 1b human pharmacokinetic data (Urva et al., Lancet 2022).[5] Pharmacokinetics are dose-proportional across the 0.5–12 mg range. The C20 fatty diacid conjugation enables albumin binding, extending the half-life to support the once-weekly subcutaneous dosing interval. See Retatrutide half-life and pharmacokinetics for full PK data.

  • Meaningful appetite suppression was observed within the first 4 weeks in Phase 2 obesity trial data. Statistically significant body weight reduction was detectable at approximately week 8. Weight loss accrued progressively without plateau over 48 weeks in the Phase 2 trial,[22] and continued to accrue through 80 weeks in TRIUMPH-1.[9] The dose-escalation period is when GI adverse events are most prominent.

  • Retatrutide is a 39-amino acid acylated peptide engineered to co-activate three G-protein-coupled receptors (GIPR, GLP-1R, GCGR).[6][14] A C20 fatty diacid moiety is attached via a lysine-17 linker, enabling albumin binding and the ~6-day half-life that supports once-weekly dosing.[5][14] At the GIPR it is approximately 8.9× more potent than endogenous GIP; it is less potent than natural ligands at the GLP-1R and GCGR.[14]

  • Eli Lilly and Company (Indianapolis, Indiana, US), internal designation LY3437943. Eli Lilly is the sponsor of the TRIUMPH Phase 3 program and is expected to file the NDA with the FDA in Q4 2026 following the May 2026 TRIUMPH-1 results readout.[21]

  • Retatrutide adds GIP and glucagon receptor activation to GLP-1 agonism. In Phase 3 data, Retatrutide at 12 mg produced 28.3% mean weight reduction at 80 weeks (TRIUMPH-1).[9] Semaglutide 2.4 mg produced approximately 14.9% at 68 weeks in its Phase 3 STEP 1 trial.[17] In pooled Phase 2 Retatrutide data, 64% of 12 mg participants achieved at least 20% weight loss versus approximately 1% with placebo.[17] No controlled head-to-head trial has been published.

  • Subcutaneous injection, once weekly — the only route of administration in all published Phase 1–3 clinical data.[5][1][9] The once-weekly interval is enabled by the approximately 6-day half-life resulting from albumin-binding C20 fatty diacid conjugation.[14] Dose escalation is used from a lower starting dose every 4 weeks to reach the maintenance dose (4 mg, 9 mg, or 12 mg in TRIUMPH-1).[9]

  • Investigational as of mid-2026 — no approved indication in the US or any jurisdiction. Phase 3 TRIUMPH-1 data were reported May 2026. NDA submission to the FDA is anticipated Q4 2026. Under a standard 10-month FDA review, approval would be projected late 2027 to Q1 2028.[21] Retatrutide may qualify for priority review; that determination depends on the regulatory pathway Eli Lilly pursues.

  • Class-effect data from analogous compound withdrawal studies indicate most weight is regained within 12 months of stopping treatment: semaglutide STEP 4 and tirzepatide SURMOUNT-4 both documented substantial regain after switching to placebo.[19] No Retatrutide-specific long-term discontinuation trial has been published. The mechanism is recovery of appetite-regulatory signaling once GIP/GLP-1/glucagon receptor agonism is removed. See Retatrutide side effects for class-effect context.

  • Three G-protein-coupled receptors: GIPR (glucose-dependent insulinotropic polypeptide receptor), GLP-1R (glucagon-like peptide-1 receptor), and GCGR (glucagon receptor).[6] All three are expressed across gut, brain, liver, adipose, and muscle — tissues central to energy homeostasis. Cryo-EM structural studies confirmed simultaneous binding to all three at near-atomic resolution.[6] Retatrutide is approximately 8.9× more potent at GIPR than endogenous GIP.[14]